Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors

[1]  Minhu Chen,et al.  Sunitinib is effective and tolerable in Chinese patients with advanced pancreatic neuroendocrine tumors: a multicenter retrospective study in China , 2017, Cancer Chemotherapy and Pharmacology.

[2]  H. Guchelaar,et al.  Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis , 2017, Acta oncologica.

[3]  E. Raymond,et al.  The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors. , 2017 .

[4]  Tetsuhide Ito,et al.  Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms , 2017, Journal of hepato-biliary-pancreatic sciences.

[5]  Xihong Lin,et al.  Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors , 2017, The oncologist.

[6]  R. Jensen,et al.  Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study. , 2015, Japanese journal of clinical oncology.

[7]  J. Ahn,et al.  RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  M. Tan,et al.  Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib , 2015, Targeted Oncology.

[9]  H. Akaza,et al.  Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients , 2015, Japanese journal of clinical oncology.

[10]  K. Kihara,et al.  Pharmacokinetic-pharmacodynamic analysis of sunitinib-induced thrombocytopenia in Japanese patients with renal cell carcinoma. , 2015, Biological & pharmaceutical bulletin.

[11]  E. Raymond,et al.  Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors. , 2014, Cancer treatment reviews.

[12]  Y. Najjar,et al.  A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. , 2014, European journal of cancer.

[13]  Kazuhiko Yoshida,et al.  Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off. , 2014, Japanese journal of clinical oncology.

[14]  T. Nishida,et al.  Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor , 2013, Investigational New Drugs.

[15]  N. Nonomura,et al.  Importance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma , 2012, Medical Oncology.

[16]  J. Burke,et al.  Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Y. Bang,et al.  Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles , 2011, Oncology.

[18]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[19]  T. Miki,et al.  Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. , 2010, Japanese journal of clinical oncology.

[20]  T. Nishida,et al.  Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate , 2010, Investigational New Drugs.

[21]  G. Demetri,et al.  Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis , 2010, Cancer Chemotherapy and Pharmacology.

[22]  M. Socinski,et al.  Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer , 2009, British Journal of Cancer.

[23]  Xin Huang,et al.  Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Blay,et al.  Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. , 2009, European journal of cancer.

[25]  Dongwoo Kang,et al.  A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients , 2009, Clinical Cancer Research.

[26]  G. Demetri,et al.  Molecular basis for sunitinib efficacy and future clinical development , 2007, Nature Reviews Drug Discovery.

[27]  L. Chow,et al.  Sunitinib: from rational design to clinical efficacy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Desai,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[29]  M. Fjällskog,et al.  Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  Song-Cheol Kim,et al.  Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor , 2016, Cancer Chemotherapy and Pharmacology.

[31]  R. Jensen,et al.  Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis , 2014, Journal of Gastroenterology.

[32]  F. Bosman,et al.  WHO Classification of Tumours of the Digestive System , 2010 .